



Cite this: *Chem. Commun.*, 2015, 51, 17775

DOI: 10.1039/c5cc90543e

www.rsc.org/chemcomm

## Correction: Acid-labile boronate-bridged dextran–bortezomib conjugate with up-regulated hypoxic tumor suppression

Weiguo Xu, Jianxun Ding,\* Lingyu Li, Chunsheng Xiao, Xiuli Zhuang and Xuesi Chen

Correction for 'Acid-labile boronate-bridged dextran–bortezomib conjugate with up-regulated hypoxic tumor suppression' by Weiguo Xu *et al.*, *Chem. Commun.*, 2015, **51**, 6812–6815.

The annotation in Fig. 3A was incorrect, and the unit of the half-maximal inhibitory concentration ( $IC_{50}$ ) in Fig. 3B was wrong. The correct version of Fig. 3 is shown below.




Fig. 3 *In vitro* cytotoxicities (A) and  $IC_{50}$ s (B) of Dex–BTZ and BTZ after incubation for 48 h toward HepG2 cells. The data were presented as mean  $\pm$  standard deviation ( $n = 3$ , \* $p < 0.05$ , # $p < 0.001$ ).

In addition, the unit for the  $IC_{50}$  values stated in lines 5 and 7 of the right column of page 3 is incorrectly displayed as “nM”. The correct unit is “ $\mu M$ ”.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

